Home » Healthcare » Pharmaceuticals » Multiple Myeloma Treatment Market

Multiple Myeloma Treatment Market, By Type (Drug Therapy, Stem Cell Transplantation, Biophosphonates, Radiation Therapy, & Surgical Therapy) – Growth, Future Prospects, And Competitive Analysis, 2017 -2025

Price: $4999

Published: | Report ID: 14263 | Report Format : PDF

Market Insights

The report titled “Multiple Myeloma Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” offers strategic insights into the overall multiple myeloma treatment market along with the market size and estimates for the duration of 2015–2025. The research study in question provides an in-depth examination of multiple myeloma market segments based on the type and different geographies further subdivided by countries. According to Myeloma UK, in myeloma, plasma cells become abnormal, multiply uncontrollably, and release only one type of antibody known as paraprotein, which has no useful function. It is often through the measurement of this paraprotein that myeloma is diagnosed and monitored.

For the purpose of this study, the global multiple myeloma treatment market is segmented on the basis of type into drug therapy, stem cell transplantation, bisphosphonates, radiation therapy, and surgical therapy. Drug therapy is further segmented into monoclonal antibodies, immunomodulatory drugs, proteasome inhibitors, chemotherapy, histone deacetylase inhibitors, and corticosteroids. Market size estimates and forecasts for these segments for the period 2015–2025 are provided in terms of USD million, along with the respective compounded annual growth rates (CAGRs) for the period 2017–2025, considering 2016 as the base year.

The geographical segmentation of the multiple myeloma treatment market comprised regions such as North America, Europe, Asia-Pacific, Latin America & the Middle East, and Africa. Each geographical region is further split to provide market revenue for select countries such as the U.S., Canada, the U.K., Germany, China, Japan, Brazil, Mexico, Saudi Arabia, South Africa, and other countries. The market size and forecast for these segments during 2015–2025 and their CAGRs for the period 2017–2025 are provided in this report.

The multiple myeloma treatment market is observed as the most diversified and competitive market, comprising a large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are Celgene Corporation, Janssen Biotech, Inc., Bristol-Myers Squibb Company, Novartis AG, Millennium Pharmaceuticals, Amgen, Inc., Genzyme Corporation, and Juno Therapeutics, among others.

Based on the type of therapy, the global multiple myeloma market is segmented as follows:

  • Drugs Therapy
  • Monoclonal Antibodies
  • Daratumumab
  • Elotuzumab
  • Immunomodulatory Drugs
  • Lenalidomide
  • Pomalidomide
  • Thalidomide
  • Proteasome Inhibitors
  • Ixazomib
  • Bortezomib
  • Carfilzomib
  • Chemotherapy
  • Liposomes containing doxorubicin HCl
  • Melphalan
  • Cyclophosphamide
  • Histone deacetylase inhibitor
  • Panobinostat
  • Corticosteroids
  • Dexamethasone
  • Prednisone
  • Stem Cell Transplantation
  • Allogenic stem cell transplants
  • Autologous stem cell transplants
  • Bisphosphonates
  • Radiation Therapy
  • Surgical Therapy

In 2016, drug therapy dominated the market due to the incessant market entry of novel drug therapies, the most convenient mode of treatment, and the rising demand for targeted therapy and biological drugs. These drugs enhance the immune system cells that identify and attack cancer cells. Biologic therapies are expected to benefit from the rising preference among medical practitioners to implement biologics owing to their established clinical profile. Recently, the approval of new monoclonal antibodies, such as Darzalex, Pomalyst, and Empliciti, is anticipated to drive the growth of this market segment in the near future. Furthermore, in August 2017, the FDA approved chimeric antigen receptor (CAR) T-cell therapy for advanced leukemia, which is currently in clinical trials for multiple myeloma, and its approval is expected to boost the growth of the multiple myeloma treatment market in the near future.

For the purpose of this study, the global multiple myeloma treatment market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

In the base year 2016, North America accounted for the largest share in the global multiple myeloma treatment market due to key driving factors such as the rising prevalence of multiple myeloma, high awareness associated with early cancer diagnosis and treatment, supportive reimbursement policies, and developed healthcare infrastructure. The American Cancer Society estimates that in 2017, about 30,280 new cases will be diagnosed in the United States, and about 12,590 deaths are expected to occur. Thus, the demand for novel drug therapies is expected to increase in the near future. During the forecast period of 2017–2025, Asia Pacific was observed as the fastest growing region due to key driving factors such as the rising prevalence of multiple myeloma in developing countries, increasing awareness associated with an early cancer diagnosis, developing healthcare infrastructure, and mounting demand for novel drug therapies.

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Multiple Myeloma Treatment Market Portraiture
2.1.1. Global Multiple Myeloma Treatment Market, By Type, 2016 (US$ Mn)
2.1.2. Global Multiple Myeloma Treatment Market, by Geography, 2016 Vs 2025 (Value %)

Chapter 3. Multiple Myeloma Treatment Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Multiple Myeloma: Epidemiology
3.3. Multiple Myeloma Treatment: Future Trends
3.4. Drivers
3.5. Challenges
3.6. Opportunities
3.7. Attractive Investment Proposition, by Geography, 2016
3.8. Major Agreements, Partnerships and Collaborations
3.9. Competitive Landscape
3.9.1. Competitive Landscape, by Key Players, 2016

Chapter 4. Global Multiple Myeloma Treatment Market, by Type, 2015 – 2025 (US$ Mn)
4.1. Overview
4.1.1. Attractive Investment Proposition: Global Multiple Myeloma Treatment Market, by Type
4.2. Drugs Therapy
4.2.1. Monoclonal Antibodies
4.2.1.1. Daratumumab
4.2.1.2. Elotuzumab
4.2.2. Immunomodulatory Drugs
4.2.2.1. Lenalidomide
4.2.2.2. Pomalidomide
4.2.2.3. Thalidomide
4.2.3. Proteasome Inhibitors
4.2.3.1. Ixazomib
4.2.3.2. Bortezomib
4.2.3.3. Carfilzomib
4.2.4. Chemotherapy
4.2.4.1. Doxorubicin HCl liposome
4.2.4.2. Melphalan
4.2.4.3. Cyclophosphamide
4.2.5. Histone deacetylase inhibitor
4.2.5.1. Panobinostat
4.2.6. Corticosteroids
4.2.6.1. Dexamethasone
4.2.6.2. Prednisone
4.3. Stem Cell Transplantation
4.3.1. Allogenic Stem Cell Transplants
4.3.2. Autologous Stem Cell Transplants
4.4. Biophosphonates
4.5. Radiation Therapy
4.6. Surgical Therapy

Chapter 5. Global Multiple Myeloma Treatment Market: Pipeline Analysis
5.1. Overview
5.2. Phase III (Market estimations by 2025)
5.2.1. Venetoclax (ABT-199) (AbbVie, Inc. & Genentech, Inc.)
5.2.2. MLN9708 (PETHEMA Foundation; Celgene; Millennium Pharmaceuticals, Inc.)
5.2.3. M-VTD-PACE & TT3-LITE Regimen (L-TT3) (University of Arkansas; Millennium Pharmaceuticals, Inc.)
5.2.4. Others
5.3. Phase II (Qualitative Information)
5.4. Phase I (Qualitative Information)
5.5. Preclinical Studies (Quantitative Information)

Chapter 6. Global Multiple Myeloma Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
6.1. Overview
6.2. North America Multiple Myeloma Treatment Market Analysis, 2015 – 2025
6.2.1. North America Multiple Myeloma Treatment Market, By Type, 2015 – 2025 (US$ Mn)
6.2.2. North America Multiple Myeloma Treatment Market, by Country, 2015 – 2025 (US$ Mn)
6.2.2.1. U.S.
6.2.2.2. Canada
6.3. Europe Multiple Myeloma Treatment Market Analysis, 2015 – 2025
6.3.1. Europe Multiple Myeloma Treatment Market, By Type, 2015 – 2025 (US$ Mn)
6.3.2. Europe Multiple Myeloma Treatment Market, by Country, 2015 – 2025 (US$ Mn)
6.3.2.1. U.K.
6.3.2.2. Germany
6.3.2.3. France
6.3.2.4. Spain
6.3.2.5. Italy
6.3.2.6. Rest of Europe
6.4. Asia Pacific Multiple Myeloma Treatment Market Analysis, 2015 – 2025
6.4.1. Asia Pacific Multiple Myeloma Treatment Market, By Type, 2015 – 2025 (US$ Mn)
6.4.2. Asia Pacific Multiple Myeloma Treatment Market, by Country, 2015 – 2025 (US$ Mn)
6.4.2.1. Japan
6.4.2.2. China
6.4.2.3. India
6.4.2.4. Rest of APAC
6.5. Latin America Multiple Myeloma Treatment Market Analysis, 2015 – 2025
6.5.1. Latin America Multiple Myeloma Treatment Market, By Type, 2015 – 2025 (US$ Mn)
6.5.2. Latin America Multiple Myeloma Treatment Market, by Country, 2015 – 2025 (US$ Mn)
6.5.2.1. Brazil
6.5.2.2. Mexico
6.5.2.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Multiple Myeloma Treatment Market Analysis, 2015 – 2025
6.6.1. MEA Multiple Myeloma Treatment Market, by Type, 2015 – 2025 (US$ Mn)
6.6.2. MEA Multiple Myeloma Treatment Market, by Region, 2015 – 2025 (US$ Mn)
6.6.2.1. UAE
6.6.2.2. Saudi Arabia
6.6.2.3. South Africa
6.6.2.4. Rest of MEA

Chapter 7. Company Profiles
7.1. Janssen Biotech, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Bristol-Myers Squibb
7.3. Novartis AG
7.4. Millennium Pharmaceuticals
7.5. Celgene Corporation
7.6. Kesios Therapeutics Limited
7.7. Amgen, Inc.
7.8. Genzyme Corporation
7.9. Juno Therapeutics
7.10. Abbvie, Inc.
7.11. Array BioPharma
7.12. Karyopharm Therapeutics
7.13. Merck KGaA
7.14. Sanofi S.A
7.15. Takeda Pharmaceutical Industries Ltd.

List of Figures

FIG. 1 Multiple Myeloma Treatment: Market Segmentation
FIG. 2 Global Multiple Myeloma Treatment Market Share, By Type, 2016 (US$ Mn)
FIG. 3 Global Multiple Myeloma Treatment Market, by Geography, 2016 Vs 2025 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography, 2016
FIG. 5 Market Competition Landscape, by Key Players, 2016
FIG. 6 Global Daratumumab Market In Multiple Myeloma Treatment, 2015 – 2025 (US$ Mn)
FIG. 7 Global Elotuzumab Market In Multiple Myeloma Treatment, 2015 – 2025 (US$ Mn)
FIG. 8 Global Lenalidomide Market In Multiple Myeloma Treatment, 2015 – 2025 (US$ Mn)
FIG. 9 Global Pomalidomide Market In Multiple Myeloma Treatment, 2015 – 2025 (US$ Mn)
FIG. 10 Global Thalidomide Market In Multiple Myeloma Treatment, 2015 – 2025 (US$ Mn)
FIG. 11 Global Ixazomib Market In Multiple Myeloma Treatment, 2015 – 2025 (US$ Mn)
FIG. 12 Global Bortezomib Market In Multiple Myeloma Treatment, 2015 – 2025 (US$ Mn)
FIG. 13 Global Carfilzomib Market In Multiple Myeloma Treatment, 2015 – 2025 (US$ Mn)
FIG. 14 Global Doxorubicin HCl liposome Market In Multiple Myeloma Treatment, 2015 – 2025 (US$ Mn)
FIG. 15 Global Melphalan Market In Multiple Myeloma Treatment, 2015 – 2025 (US$ Mn)
FIG. 16 Global Cyclophosphamide Market In Multiple Myeloma Treatment, 2015 – 2025 (US$ Mn)
FIG. 17 Global Panobinostat Market In Multiple Myeloma Treatment, 2015 – 2025 (US$ Mn)
FIG. 18 Global Dexamethasone Market In Multiple Myeloma Treatment, 2015 – 2025 (US$ Mn)
FIG. 19 Global Prednisone Market In Multiple Myeloma Treatment, 2015 – 2025 (US$ Mn)
FIG. 20 Global Biophosphonates Market In Multiple Myeloma Treatment, 2015 – 2025 (US$ Mn)
FIG. 21 Global Radiation Therapy Market In Multiple Myeloma Treatment, 2015 – 2025 (US$ Mn)
FIG. 22 Global Surgical Therapy Market In Multiple Myeloma Treatment, 2015 – 2025 (US$ Mn)
FIG. 23 Global Venetoclax (ABT-199) Market In Multiple Myeloma Treatment (Forecast By 2025) (US$ Mn)
FIG. 24 Global MLN9708 Market In Multiple Myeloma Treatment (Forecast By 2025) (US$ Mn)
FIG. 25 Global M-VTD-PACE Market In Multiple Myeloma Treatment (Forecast By 2025) (US$ Mn)
FIG. 26 Global TT3-LITE Regimen (L-TT3) Market In Multiple Myeloma Treatment (Forecast By 2025) (US$ Mn)
FIG. 27 U.S. Multiple Myeloma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 28 Canada Multiple Myeloma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 29 U.K. Multiple Myeloma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 30 Germany Multiple Myeloma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 31 France Multiple Myeloma Treatment Market, 2015-2025 (US$ Mn)
FIG. 32 Spain Multiple Myeloma Treatment Market, 2015-2025 (US$ Mn)
FIG. 33 Italy Multiple Myeloma Treatment Market, 2015-2025 (US$ Mn)
FIG. 34 Rest Of Europe Multiple Myeloma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 35 Japan Multiple Myeloma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 36 China Multiple Myeloma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 37 India Multiple Myeloma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 38 Rest Of Asia Pacific Multiple Myeloma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 39 Brazil Multiple Myeloma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 40 Mexico Multiple Myeloma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 41 Rest Of Latin America Multiple Myeloma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 42 UAE Multiple Myeloma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 43 Saudi Arabia Multiple Myeloma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 44 South Africa Multiple Myeloma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 45 Rest Of Middle East And Africa Multiple Myeloma Treatment Market, 2015 – 2025 (US$ Mn)

List of Tables

TABLE 1 Global Multiple Myeloma Treatment Market, By Type, 2015 – 2025 (US$ Mn)
TABLE 2 Global Multiple Myeloma Treatment Market, By Geography, 2015 – 2025 (US$ Mn)
TABLE 3 Global Drug Therapy Market in Multiple Myeloma Treatment, 2015 – 2025 (US$ Mn)
TABLE 4 Global Monocloncal Antibodies Market in Multiple Myeloma Treatment, 2015 – 2025 (US$ Mn)
TABLE 5 Global Immunomodulatory Drugs Market in Multiple Myeloma Treatment, 2015 – 2025 (US$ Mn)
TABLE 6 Global Proteasome Inhibitors Market in Multiple Myeloma Treatment, 2015 – 2025 (US$ Mn)
TABLE 7 Global Chemotherapy Market in Multiple Myeloma Treatment, 2015 – 2025 (US$ Mn)
TABLE 8 Global Histone deacetylase inhibitor Market in Multiple Myeloma Treatment, 2015 – 2025 (US$ Mn)
TABLE 9 Global Corticosteroids Market in Multiple Myeloma Treatment, 2015 – 2025 (US$ Mn)
TABLE 10 Global Stem Cell Transplantation Market in Multiple Myeloma Treatment, 2015 – 2025 (US$ Mn)
TABLE 11 North America Multiple Myeloma Treatment Market, By Type, 2015 – 2025 (US$ Mn)
TABLE 12 North America Multiple Myeloma Treatment Market, By Country, 2015 – 2025 (US$ Mn)
TABLE 13 Europe Multiple Myeloma Treatment Market, By Type, 2015 – 2025 (US$ Mn)
TABLE 14 Europe Multiple Myeloma Treatment Market, By Country, 2015 – 2025 (US$ Mn)
TABLE 15 Asia Pacific Multiple Myeloma Treatment Market, By Type, 2015 – 2025 (US$ Mn)
TABLE 16 Asia Pacific Multiple Myeloma Treatment Market, By Country, 2015 – 2025 (US$ Mn)
TABLE 17 Latin America Multiple Myeloma Treatment Market, By Type, 2015 – 2025 (US$ Mn)
TABLE 18 Latin America Multiple Myeloma Treatment Market, By Country, 2015 – 2025 (US$ Mn)
TABLE 19 Middle East And Africa Multiple Myeloma Treatment Market, By Type, 2015 – 2025 (US$ Mn)
TABLE 20 Middle East And Africa Multiple Myeloma Treatment Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 21 Janssen Biotech, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 Bristol-Myers Squibb: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 24 Millennium Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 25 Celgene Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 26 Kesios Therapeutics Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 27 Amgene, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 28 Genzyme Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 29 Juno Therapeutics: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 30 Abbvie, Inc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 31 Array BioPharma: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 32 Karyopharm Therapeutics: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 33 Merck KGaA: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 34 Sanofi S.A : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 35 Takeda Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)

Frequently Asked Questions:

What is the size of Multiple Myeloma Treatment Market?

The market for Multiple Myeloma Treatment Market is expected to reach USD 21,221.8 Mn By 2025.

What is the Multiple Myeloma Treatment Market CAGR?

The Multiple Myeloma Treatment Market is expected to see significant CAGR growth over the coming years, at 11.0%.

What is the Forecast period considered for Multiple Myeloma Treatment Market?

The report is forecasted from 2017-2025.

What is the base year considered for Multiple Myeloma Treatment Market?

The base year of this report is 2016.

Who are the major players in this market?

Celgene Corporation, Janssen Biotech, Inc., Bristol-Myers Squibb Company, Novartis AG, Millennium Pharmaceuticals, Amgen, Inc., Genzyme Corporation, and Juno Therapeutics are some of the major players in the global market.

Obesity Diabetes Drugs Market

Published:
Report ID: 43145

Trigeminal Neuralgia Treatment Market

Published:
Report ID: 11788

Pompe Disease Therapeutics Market

Published:
Report ID: 5989

Pre-Menstrual Syndrome Treatment Market

Published:
Report ID: 11248

Vial Adaptors for Reconstitution Drug Market

Published:
Report ID: 15561

Psychedelic Medicine Market

Published:
Report ID: 41606

Hospital Infection Prevention And Control Market

Published:
Report ID: 7217

Nanoparticle Formulation Market

Published:
Report ID: 41106

Animal Drug Compounding Market

Published:
Report ID: 40870

Antibiotics Market

Published:
Report ID: 40728

Conjugation and Labeling Services Market

Published:
Report ID: 40756

Antiviral Drugs Market

Published:
Report ID: 40681

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN